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Abstract
Background—The Cavidi viral load assay and the ultra-sensitive p24 antigen assay (Up24 Ag)
have been suggested as more feasible alternatives to PCR-based HIV viral load assays for use in
monitoring patients infected with HIV-1 in resource-limited settings.
Objectives—To describe the performance of the Cavidi ExaVir Load™ assay (version 2.0) and
two versions of the Up24 antigen assay and to characterize their agreement with the Roche
Monitor HIV-1 RNA assay (version 1.5).
Study Design—Observational study using a convenience sample of 342 plasma specimens from
108 patients enrolled in two ACTG clinical trials to evaluate the performance characteristics of the
Up24 Ag assay using two different lysis buffers and the Cavidi ExaVir Load™ assay.
Results—In analysis of agreement with the Roche assay, the Cavidi assay demonstrated
superiority to the Up24 Ag assays in accuracy and precision, as well as sensitivity, specificity, and
positive and negative predictive values for HIV-1 RNA ≥400, ≥1000 and ≥5000 copies/mL.
Logistic performance curves indicated that the Cavidi assay was superior to the Up24 assays for
viral loads greater than 650 copies/mL.
Conclusions—The results suggest that the Cavidi ExaVir Load assay could be used for
monitoring HIV-1 viral load in resource-limited settings.
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Background
HIV-1 plasma viral load assays and CD4 cell counts have proven useful in initiating
therapeutic regimens and assessing adherence and response to treatment. Adequately
sensitive assays are essential for prompt detection of virologic treatment failure, and
thereby, prevention of the evolution and transmission of drug-resistant strains of HIV. As
access to antiretroviral (ARV) drugs expands, attention has turned to the feasibility of
performing viral load assays in resource-limited countries. Cost and technical complexity
tend to limit feasibility of amplification-based methods currently approved by the FDA. The
Cavidi ExaVir Load™ assay1–17 of reverse transcriptase (RT) activity, and the ultra-
sensitive p24 antigen (Up24 Ag) assay8, 16, 18–21 are noted for their lower cost and
simpler technical requirements. Furthermore, RT assays can be used to evaluate phenotypic
drug resistance22–24.
Objectives
We evaluated agreement between the Roche HIV RNA Amplicor Monitor assay (version
1.5) and three alternative assays: the Cavidi assay, the Up24 Ag assay using the
manufacturer’s lysis buffer (Up24-m), the Up24 Ag assay adding an external buffer for
enhanced lytic reaction (Up24-JS)21.
Study Design
This study was approved by the Adult AIDS Clinical Trials Group (ACTG) as New Works
Concept Sheet 227 and by the Institutional Review Board of The University of North
Carolina at Chapel Hill (UNC).
Clinical Samples
We obtained baseline plasma samples from 23 participants in ACTG protocol 20125,26 and
longitudinally-collected samples from 85 participants in ACTG protocol 30727,28. The
Roche RNA assay was always performed. Other assays were prioritized if sample volume
was limited: Cavidi RT, Up24-JS, then Up24-m. Prioritization resulted in some assay values
being intentionally missing. For 273 specimens, volume was sufficient for all assays. For 36,
neither Up24 antigen assay was performed. For 32, the Up24-m assay was not performed.
For one, both Up24 assays were performed but the Cavidi assay was not because less than 1
ml of plasma was available.
Roche HIV RNA Amplicor Monitor Assay, Version 1.5
Plasma viral loads were measured using the Amplicor HIV-1 Monitor™ assay, version 1.5
(Roche Molecular Systems, Branchburg, NJ.) The lower limit of quantification (LLQ) was
400 copies/mL.
Cavidi ExaVir Load™ Assay
The Cavidi assay (Cavidi AB, Uppsala, Sweden) was performed following the package
insert. For each sample, RT activity was measured relative to a serially diluted reference
enzyme standard of known concentration. Results were reported as fentograms RT per
milliliter (fg/mL) and converted to HIV-1 RNA copies per mL equivalents (cps/mL eqs)
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using the ExaVir ™ Load kit version 2.0 and ExaVir ™ Load Analyzer software version
1.61
Ultra-Sensitive p24 Antigen Assays
Samples were assayed by Up24-m and Up24-JS on the same plate following the standard
procedure using the HIV-1 p24 enzyme-linked immunosorbent (ELISA) assay kit (catalog
no. NEK050 / 050A / 050 / B HIV-1 ELISA; Perkin Elmer Life Sciences, Inc, Waltham,
MA) and the p24-specific viral load ELAST® amplification system kit (catalog no.
NEP116VL). Specimens were assayed using the manufacturer’s buffer (Up24-m assay) and
separately using a previously described external buffer21 (Up24-JS assay). For Up24-m,
250ul of assay dissociation buffer was added to 50ul of sample, followed by boiling for
5min. For Up24-JS, 25ul of buffer was first added to 50ul of the sample, incubated for
10min, followed by addition of 225ul of assay dissociation buffer and boiling for 5min.
Samples were cooled and processed per package inserts. Sample absorbance was measured
in kinetic and endpoint modes using Quanti-Kin detection software (Rilab, Genoa, Italy) and
reported as p24 antigen fg/mL.
Statistical Analysis Strategy
Analysis of inter-assay agreement on log10 scale focused on Bland-Altman plots and other
graphical figures computed using bivariate longitudinal mixed-effects models for assay
pairs. Log10 assay pairs were assumed to follow a bivariate Gaussian distribution
characterized by two sets of inter- and intra- subject variance components. The subject-
specific random effect for one assay was assumed to be correlated with that of the other
assay. The models were fitted via an algorithm designed to cope with a mix of missing, left-
censored, and complete values, while accounting for correlation within persons and between
assays, and avoiding use of imputation methods.29–32. Every pair of values was included in
the fitting of these models unless both values were intentionally missing. Parameter
estimates obtained were then used to compute confidence intervals, estimates, tests, and
predicted locations of left-censored and missing values. Descriptive assay-specific
univariate linear mixed-effects model were also fitted.
In analyses of agreement in terms of dichotomized assay values, logistic models for
detection of HIV-1, conditional on the magnitude of viral load according to the Roche assay
as a covariate, were fitted using a GEE-1 algorithm33 assuming exchangeable covariance
structure. Similar models for binary indicators of whether the assays exceeded a given
threshold (e.g., 5000 cp/mL) were fitted conditional on an indicator of whether the Roche
assay exceeded that same threshold.
Sensitivity analyses were performed to examine robustness of primary results to reasonable
perturbations of assumptions and methods. All computations were performed using SAS
9.1.3 (SAS Institute, Inc., Cary, NC.)
Results
The Longitudinal Assay Data
HIV-1 was detected by the Roche assay in 80.7% (276/342) of samples. Among samples
with assay values not missing by design, HIV-1 was detected in 75.4% (257/341), 74.8%
(229/306), and 66% (181/274) by the Cavidi, Up24-JS, and Up24-m assays, respectively
(Figure 1). Fully observed pairs of values (black dots) are represented in Figure 1 along with
model-based predictions for the left-censored values (open circles) and values missing by
design (open squares.) Most samples (88.7%, 244/275) with HIV-1 RNA above the limit of
detection by Roche also had detectable HIV-1 RT by Cavidi (Figure 1). In comparison,
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85.6% (208/243) and 78.4% (171/218) of samples with HIV-1RNA above the limit of
detection by Roche also had detectable HIV-1 by Up24-JS and Up24-m, respectively.
Estimates of the mean (and total variance) for the underlying distributions of Roche, Cavidi,
Up24-JS, and Up24-m log10 values were 3.83 (1.6), 3.67 (1.8), 3.65 (2.1) and 3.29 (1.7),
respectively (Table 1). The estimate of intra-assay correlation between two Roche assays
performed at different times for an arbitrary patient was 0.78, while the estimates for Cavidi,
Up24-JS, and Up24-m assays were 0.80, 0.88, and 0.83, respectively. The estimate of inter-
assay correlation between Roche and Cavidi assays for an arbitrary patient at an arbitrary
time (r = 0.78) was larger than that for Up24-JS (r = 0.71) and Up24-m (r = 0.68).
Agreement on Viral Load
In Bland-Altman plots (Figure 2) for agreement with the Roche assay, the Up24 assays
exhibited deviations from the Roche assay that were more dispersed than those for the
Cavidi assay; i.e., the variance of the deviations from the Roche assay was smaller for the
Cavidi assay (0.73), than for the Up24-JS (1.10) and Up24-m (1.09) assays (Table 1).
Estimates of mean difference between Roche assays and alternative assays indicated
underestimation by the Cavidi (0.15 log10), Up24-JS (0.13 log10), and Up24-m (0.48 log10)
assays (Table 1); here, bias of Cavidi was small but deemed reproducible (p < 0.0033 for the
test of “no bias”.) Association between magnitude of bias and magnitude of viral load was
not detected for Cavidi, Up24-JS or Up24-m assay (Table 1 and Figure 2). The fitted models
also provided information about calibration; e.g., given any Cavidi assay value, the best
linear unbiased predictor of the corresponding log10 Roche assay was1.07 + 0.75 log10
Cavidi. The null hypothesis “calibration is unnecessary” was rejected for Cavidi, Up24-JS
and Up24-m (each p < 0.0001).
Agreement on Dichotomized Values
Relative to the Roche assay as a gold standard, Cavidi was superior to both Up24 assays in
terms of sensitivity, specificity, and positive (PPV) and negative predictive value (NPV)
(Table 2). Estimates of PPV indicated the Roche assay is highly likely to exceed a given
threshold whenever the other assay has done so. Given a Cavidi assay < 5000 cp/mL, for
example, the Roche assay is likely to be < 5000 cp/mL (NPV = 87%); in contrast, values for
the Up24 assays below this level do not ensure that the Roche assay value will be < 5000 cp/
mL (NPV = 62%, 53%).
Performance in Detection of HIV-1
Estimates of logistic performance curves representing the probability of detecting HIV-1 at
given levels of the Roche assay value indicated that Cavidi, Up24-JS, and Up24-m assays
are all likely to detect HIV-1 when viral load (per Roche) is greater than 4.5 log10 (Figure
3). For all viral load values greater than 2.8 log10, the performance curve for Cavidi was
superior to the curves for Up24-JS and Up24-m assays.
Agreement on Viral Load Change-from-Baseline
Longitudinal data from 71 subjects (234 evaluations) allowed comparison of assays in terms
of change-from-baseline (Δ) scores (Figure 4). Model-based estimates of mean Δ for Roche
was −0.51 log10 cp/mL. Similar declines were evident for Cavidi (−0.36), Up24-JS (−0.44),
and Up24-m (−0.52). Estimated correlation with ΔRoche was greatest for ΔCavidi (r = 0.87)
and less for ΔUp24-JS (r = 0.33), and ΔUp24-m (r = 0.22).
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Comparison of Other Characteristics of the Assays
The four assays were compared in terms of cost, turn-around- times, storage requirements,
additional reagent required, equipment, and degree of technologic complexity (Table 3). The
p24 antigen assay was the least expensive ($5 – $7 USD) and least complex, but still
required storage at 4°C and equipment such as a heat block, a 37°C incubator, and a ELISA
plate shaker, washer, and reader. The most complex and expensive ($20–50 USD) was the
Roche assay which also required equipment such as a thermocycler, ELISA plate washer
and reader, 37° C incubator, and a matrix automated pipette. The Cavidi assay was
intermediate in cost and complexity, but required 2–3 days to complete.
Discussion
The Cavidi assay agreed with the Roche assay more closely than either Up24 Ag assays.
Use of the alternate “JS” lysis buffer improved performance of the Up24 Ag assay as
demonstrated previously21. Relative to the Roche RNA assay as a gold standard, the Cavidi
RT assay exhibited greater accuracy and precision than the Up24 assays. Up24-m
substantially underestimated viral load (mean difference > 0.3 log10) while Up24-JS and
Cavidi RT assays did not. The differences between the Roche and Cavidi values were less
dispersed than for Up24-JS and Up24-m. The results also suggest that refinement in
calibration of the Cavidi assay (using 1.07 + 0.75 log10 Cavidi) might improve agreement
with the Roche assay. Agreement was slightly better on the change-from-baseline scale,
although for the Up24 assays it appeared that mean deviation from the Roche assay depends
on the magnitude of underlying viral load.
The WHO recently issued new treatment guidelines suggesting that antiretroviral therapies
be changed when viral load exceeds 5000 cp/mL.34 The performance of the Cavidi assay
was superior to that of the Up24 assays when considering a dichotomized assay value.
Three analytes were measured: HIV-1 RNA, HIV-1 RT, p24 antigen. While RT
concentrations were converted to cp/mL equivalents, the p24 antigen levels were expressed
as fg/mL. In addition, both the RNA and RT assays measure virion-associated components,
while the Up24 antigen assay can measure both virion-associated and free or immune-
complex-bound p24 antigen in plasma. The Cavidi RT assay was in closer agreement with
the Roche RNA assay than either of the Up24 antigen assays.
Primary analyses of assay agreement and correlation relied on methods that used all data and
did not rely on imputation.29–32 Single-imputation frequently cited in the assay-comparison
literature yields biased estimates of means, variances, standard errors, and correlations of
interest; e.g., had we imputed a value of 1.0 for all left-censored assay values prior to fitting
the models, we would have obtained smaller estimates of the inter- and intra-assay
correlations.
This study was limited to individuals infected with subtype B. Inferences about how the
assays perform when applied to other subtypes would involve extrapolation. However, the
Cavidi RT assay does not depend on particular sequences (RNA assays) or antigenic
epitopes (p24 antigen assay) and therefore should be applicable to any lentivirus, including
HIV-21. In Western Africa where co-infection with HIV-1 and HIV-2 is not uncommon,
Cavidi would provide a sum of both viral loads; the other assays do not detect HIV-2. Our
results are consistent with results from previous studies for subtype B3–5,8–11, 20,21, as well
as with results from studies that included other subtypes6,7,9,12,13–16,19. The Cavidi RT
assay is currently in use in Botswana for monitoring HIV-1 viral load12.
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This study used the standard Roche Monitor assay (LLQ = 400 cp/mL) instead of the
ultrasensitive Roche assay (LLQ = 50 cp/mL) which would have allowed additional
inferences about assay performance in the range of 50 to 400 cp/mL. However, plasma
sample volumes were not sufficient for performing the more sensitive assay and the other
assays as well. This work was performed prior to release of version 3 of the Cavidi assay4,9.
It is plausible that use of that version would produce more accurate results.
Unit costs of the assays we performed ranged from $5 to $50 per plasma sample and all
required refrigeration and use of specialized equipment that runs on electricity.
Infrastructure is often lacking in resource limited settings’ and skilled technologists are
seldom available except in a few central hospitals, reference laboratories or research
centers35. Because the turn-around time for a typical assay is at least 4–8 hours, results
would not be available on the day of collection even at the testing facility. Point of care viral
load assays are desperately needed that can provide a result while the patient waits 35, 36.
In conclusion, the performance characteristics of the Cavidi RT assay observed in this study
lend support to its use in monitoring HIV-1 viral load in resource-limited settings.
Abbreviations
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ELISA enzyme-linked immunosorbent assay
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HIV Human immunodeficiency virus
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Viral load measurements by Roche, Cavidi, Up24-JS and Up24-m assays for N = 342, 341,
306, and 274 plasma samples, respectively, are plotted: observed pairs of values (•), pairs
with one or both values left-censored (○), pairs with one value missing (□). Missing by
design and left-censored values were predicted using parameter estimates from bivariate
mixed-effects models.
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Bland-Altman plots for analysis of agreement between the Roche Monitor assay and the
Cavidi, Up24-JS, and Up24-m assays are shown. For every pair of values plotted in Figure 1
(including pairs with both values observed (•), and pairs with intentionally missing (□) or
left-censored (○) values) the average and difference of the two assay values was computed
and plotted here along with model-based upper and lower 95% prediction limits (a.k.a.
“limits of agreement”). The estimate of mean difference is indicated by a solid line segment.
For Cavidi, Up24-JS, and Up24-m, both assay values were observed (•) for 244, 208, and
171 plasma samples, respectively.
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Each logistic-linear performance curve provides estimates of the probability of detecting
HIV-1 at given levels of viral load measured by the log10 Roche Monitor. The relative
positions of the curves favor the Cavidi RT assay for viral loads greater than 2.8.
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Viral load change-from-baseline scores (Δ) for 234 plasma samples from 71 patients were
obtained from observed assay values (•), and from predictions for assay values missing by
design (□) or left-censored (○). Predicted values were computed using parameter estimates
from bivariate mixed-effects models. Among [ΔCavidi, ΔRoche] pairs of scores, k = 137
were complete, c = 97 involved censored values, and m = 0 involved missing values. Among
[ΔUp24-JS, ΔRoche] pairs, k = 117, c = 94, and m = 33. Among [ΔUp24-m, ΔRoche] pairs,
k = 92, c = 77, and m = 65.
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Table 1
Assay Agreement
Estimates are shown with 95% confidence intervals obtained from bivariate and univariate mixed-effects
models.
Roche RNA Cavidi RT Up24-JS Up24-m






















































Best Predictor of Roche
Ho“no calibration needed”
-- 1.07 + 0.75 VL
p < 0.0001
1.45 + 0.64 VL
p < 0.0001
1.59 + 0.66 VL
p < 0.0001
Comparison of entries within a row:
*
The null hypothesis “no difference among the assays” was not rejected (i.e., p ≥ 0.05)
**
The null hypothesis “no difference among the assays” was rejected (i.e., p < 0.05)
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Table 3







Cost2 $20 – $50 $15 – $20 $5 – $7
Time 1 day 2–3 days 1 day
Complexity High Medium Low to Medium
Storage 4°C 4°C and −20°C 4°C
Minimum
Specimen





























With or without external buffer.
2
Cost of kit for assaying one plasma specimen; does not include additional equipment, additional reagents, labor, quality assurance.
3
Reagents not supplied in the kit.
4
If using the external buffer: EDTA, Tris-HCL, SDS, Deoxycholic Acid, and a pH meter.
5
Equipment needed in addition to pipettes, tips, gloves and gowns that are needed for all the assays.
6
Recommended.
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